Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Luye Pharma Group ( (HK:2186) ).
Luye Pharma Group has received approval from the U.S. FDA for clinical trials of LY03020, a next-generation antipsychotic intended to treat schizophrenia. This drug is the first dual TAAR1/5-HT2C receptor agonist and aims to address the significant unmet treatment needs in the CNS therapeutic area by offering improved management of positive and negative symptoms and cognitive impairments without the adverse effects common in existing antipsychotics. This development strengthens Luye Pharma’s position in the CNS market and indicates a meaningful advancement in treatment options for schizophrenia, which affects millions globally.
More about Luye Pharma Group
Luye Pharma Group Ltd. operates in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company’s primary market focus is on Central Nervous System (CNS) therapeutic areas, including schizophrenia. They have a globally competitive CNS portfolio with products such as Erzofri, Rykindo, Ruoxinlin, and Jinyouping, and are actively engaged in clinical trials for several investigational drugs.
YTD Price Performance: -4.80%
Average Trading Volume: 1,000
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $973.5M
Find detailed analytics on 2186 stock on TipRanks’ Stock Analysis page.
